Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Inclusion Criteria

• •1. Adults aged 19 to 75 years who provide informed consent.
• •\[Part A: Type 2 Diabetes Mellitus (T2DM) Specific Criteria\]
• •2. Diagnosed with type 2 diabetes for at least 6 months, with HbA1c between 7.0% and 10.0%, despite adherence to diet and exercise therapy according to diabetes treatment guidelines.
• •3. Stable on metformin monotherapy or metformin in combination with one oral hypoglycemic agent for at least 90 days.
• •4. BMI between 18.5 kg/m² and 30.0 kg/m², with a minimum weight of 55 kg for men and 50 kg for women.
• •\[Part B: Obesity (OB) Specific Criteria\]
• •5. Failed at least one attempt at weight loss through diet and exercise.
• •6. Cohort B1: BMI ≥ 30 kg/m²
• •7. Cohort B2: BMI ≥ 27 kg/m² 8-1. Cohort B2: Diagnosed with type 2 diabetes for at least 6 months, with HbA1c between 7.0% and 10.0%.
• •8-2. Cohort B2: Received treatment with diet and exercise alone, OR stable on approved oral antidiabetic monotherapy or combination therapy for at least 90 days prior to screening.